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Objectives: Studies have suggested that ethnicity and environment may influence thyroid
disease. We aim in this study to determine the prevalence of thyroid disease among Saudi
(Arab) patients with laboratory-diagnosed obstructive sleep apnea (OSA) and the characteris-
tics and predictors of thyroid disease associated with OSA.
Methods: Serum thyroid-stimulating hormone (TSH) and free-thyroxine (FT4) levels were
measured in all patients referred to the sleep disorders center for an overnight sleep study.
The levels were measured within 4 weeks of the sleep study. Type I attended polysomnography
(PSG) was performed for all patients.
Results: During the study period, 271 patients with OSA and a mean age of 48.7  14.1 yr,
a body mass index (BMI) of 37.7  9.6 kg/m2 and an AHI of 55.2  37/hr as well as 76 non-
OSA patients with a mean age of 40.8  14.9 yr, a BMI of 33.7  8.9 kg/m2 and an AHI of
3.8  3.1/hr underwent thyroid function tests. In the OSA patients, the prevalence of newly
diagnosed clinical hypothyroidism was 0.4%, and the prevalence of newly diagnosed subclinical
hypothyroidism was 11.1%. In the non-OSA patients, the prevalence of newly diagnosed clinical
hypothyroidism was 1.4%, and the prevalence of newly diagnosed subclinical hypothyroidism
was 4%. There were no cases of clinical or subclinical hyperthyroidism in the studied group.
Female gender was the only predictor of clinical hypothyroidism.
Conclusion: In the OSA patients, the prevalence of newly diagnosed clinical hypothyroidism
was low; however, subclinical hypothyroidism was common among patients with OSA.
ª 2011 Elsevier Ltd. All rights reserved.467 1521; fax: þ966 1 467 9495.
.edu.sa, ashammam2@gmail.com (A.S. BaHammam).
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Hypothyroidism has been associated with obstructive sleep
apnea (OSA), as some symptoms for both illnesses overlap.
The proposed mechanisms for the relationship between
OSA and hypothyroidism include the deposition of muco-
proteins in the upper airway causing upper airway
obstruction, disturbances of the regulatory control of
pharyngeal dilator muscles due to neuropathy, and the
possibility of respiratory center depression.1 Thyroxine as
a replacement therapy does not always resolve the sleep
disordered breathing (SDB), and treating SDB does not cure
hypothyroidism. Thus, the recognition and treatment of
both disorders is essential.2e5 The overlap between the two
disorders may create a problem for the treating physician in
differentiating both disorders and may result in a misdiag-
nosis or under-recognition of one of the disorders. Hypo-
thyroid patients commonly suffer from SDB; however,
previous studies have reported conflicting results, and the
majority of studies have shown that hypothyroidism is
relatively uncommon among OSA patients.2,3,6e9 A preva-
lence of 1e10% has been reported in patients with OSA in
different studies using different diagnostic criteria.8,10e13
However, in a previous study designed to assess gender
differences in Saudi patients with OSA, we found that
thyroid disease prevalence was higher among women
(23.6%) compared to men (6.2%).14 Some of the previous
studies defined hypothyroidism as the presence of a high
serum thyroid-stimulating hormone (TSH) level without
commenting on thyroxine hormone level. This means that
some of the patients thought to have hypothyroidism may
actually have had subclinical hypothyroidism, which carries
different therapeutic and prognostic implications.8,12,15
Several studies have suggested that both environmental
factors and ethnicity influence the prevalence of hypo-
thyroidism.16e18 As a result, the prevalence of hypothy-
roidism in OSA patients may vary with race and
geographical region. Therefore, this study was designed to
determine the prevalence of thyroid disease based on TSH
and thyroxine levels among Saudi (Arab) patients with
laboratory-diagnosed OSA and to attempt to identify the
characteristics and predictors of thyroid disease in OSA
patients.
Methodology
In this prospective descriptive study, all consecutive
patients who were referred to the sleep disorders center
(SDC) for an overnight sleep study during the period from
January 2009 to June 2010 were included in the study.
Demographic and clinical data (history and physical exam-
ination) were obtained by a sleep medicine specialist
during the initial assessment in the SDC that included
questions related to sleep complaints, medical diagnoses
and response scales from the Wisconsin Sleep Cohort Study
questionnaire19 that primarily addresses the presenting
symptoms, sleep symptoms, medical symptoms, and other
medical conditions. The Epworth Sleepiness Scale (ESS) was
used for a subjective assessment of daytime sleepiness.20
Patients with hypoventilation (defined as a difference of
10 mmHg in EtCO2 (endtidal CO2) during sleep comparedto the awake supine value associated with sustained oxygen
desaturation that was not associated with obstructive
apneas, hypopneas or periodic breathing21), patients with
neuromuscular diseases, acutely ill patients and those who
were taking medication that might affect thyroid testing,
such as amiodarone, dopamine agonists and lithium, were
excluded. None of the studied patients was taking
hypnotics or narcotics at the time of the study. Consent was
obtained from all participants, and the study was approved
by the institutional review board.
Thyroid evaluation
Serum TSH and thyroxine (FT4) levels were measured in the
morning within 4 weeks of the sleep study using the elec-
trochemiluminescence immunoassay (ECLIA) method22
(Roche Diagnostics GmbH, Mannheim, Germany). The
normal ranges for TSH and FT4 are 0.25e5.0 mIU/mL and
10.3e25.8 pmol/L, respectively. Clinical hypothyroidism
was diagnosed for the following conditions: 1) if the
patients had been diagnosed by the referring physician with
hypothyroidism and had been on thyroxine replacement
based on chart documentation (this will be termed known
clinical hypothyroidism) and 2) if the TSH level was
>5.0 mIU/mL and the FT4 level was <10.3 pmol/L while the
patient was in the SDC (newly diagnosed clinical hypothy-
roidism). Subclinical hypothyroidism was defined as a serum
TSH concentration > 5.0 mIU/mL when the serum FT4 level
was within the reference range.23 Clinical hyperthyroidism
was defined as a TSH level < 0.25 mIU/mL and an FT4 level
more than 25.8 pmol/L. Subclinical hyperthyroidism was
defined as a TSH level < 0.25 mIU/mL in the presence of
a normal FT4 level.23
Polysomnography
Standard in-lab type I polysomnography (PSG) was per-
formed. Manual scoring of the electronic raw data was
completed in accordance with established criteria, and the
scorer was blind to the thyroid function results.24 Respira-
tory events were defined according to the American
Academy of Sleep Medicine (AASM) criteria.24 We defined
mild OSA as an AHI score from 5 to 15/h; moderate OSA as
an AHI score from >15 to 30/h; and severe OSA as an AHI
score greater than 30/h.21 OSA was defined according to the
International Classification of Sleep Disorders (ICSD 2005).25
Statistical analysis
The data were expressed as mean and standard deviation
(SD) in both the text and the tables. Student t-tests were
used to compare the means for continuous data. If the
normality test failed, the ManneWhitney test was used. For
categorical data, the chi-square test was used. The results
were considered statistically significant if p < 0.05. To
explore the associations between independent factors and
clinical and subclinical hypothyroidism, a preliminary
analysis used a univariate logistic regression model; one
explanatory variable was tested in the model at a time.
Subsequently, variables with significant p-values were
Thyroid disease in OSA patients 1757evaluated further using a multivariate logistic regression
model. SPSS (version 17; Chicago, IL, USA) was used for the
analyses.Results
Description of subjects
A total of 418 patients (62% males) were referred to the
sleep disorders center from different specialties for an
overnight sleep study during the study period. All the
patients were evaluated by a sleep disorders specialist
before undergoing overnight sleep studies. OSA was diag-
nosed in 325 patients (66% males). Seventy-one OSA
patients declined to participate in the study. Among the 93
subjects who did not have OSA, 17 subjects declined to
participate in the study. Therefore, 271 OSA patients (62%
males) with a mean age of 48.7  14.1 yr, a body mass index
(BMI) of 37.7  9.6 kg/m2 and an AHI of 55.2  37/hr; and
76 non-OSA patients (49% males) with a mean age of
40.8  14.9 yr, a BMI of 33.7  8.9 kg/m2 and an AHI of
3.8  3.1/hr participated in the study. The prevalence of
smoking and other common chronic illnesses in the OSA
patients was as follows: smoking (11.4%), hypertension
(43.5%), coronary artery disease (14%), diabetes mellitus
(36.2%), compensated heart failure (1.5%), and bronchial
asthma (34.7%). In the non-OSA patients, the prevalence
was as follows: smoking (6.6%), hypertension (35.5%),
coronary artery disease (5.3%), heart failure (0%), diabetes
mellitus (26.3%), and bronchial asthma (34.7%).
In the OSA patients, the TSH levels ranged from 0.01 to
44.24 (3.1  3.5) mIU/mL, and the FT4 levels ranged from 8
to 28 (15.0  2.6) pmol/L; for the non-OSA subjects, the
TSH levels ranged from 0.16 to 15.5 (2.6  2.1) mIU/mL, and
the FT4 levels ranged from 1.0 to 22.0 (14.4  2.8) pmol/L.
Overall, the TSH levels in all study participants ranged from
0.01 to 44.24 (3.0  3.2) mIU/mL, and the FT4 levels ranged
from 1.0 to 28.0 (14.8  2.6) pmol/L. TSH and FT4
measurements were repeated for 20 patients with
subclinical hypothyroidism within 4e8 weeks of the first
assessment, and the initial findings were confirmed. There
was no difference in the distribution of OSA severity for the
different categories of thyroid function.
Thyroid disease among subjects
Clinical hypothyroidism
Among the OSA patients, a total of 26 (9.6%) had been
previously diagnosed by their treating physicians with
clinical hypothyroidism and had started taking a thyroxine
replacement. One (0.4%) patient was newly diagnosed at
the SDC based on high TSH and low FT4 levels. The preva-
lences of clinical hypothyroidism among female and male
OSA patients were 23.9% (21 out of 88) and 3.8% (6 of 156),
respectively.
Table 1 presents a comparison of the demographic and
polysomnographic data for the OSA patients with and
without clinical hypothyroidism. Hypothyroid patients were
heavier, had a higher prevalence of hypertension and dia-
betes mellitus, and spent more time with an SaO2 < 90.Table 2 presents within-gender comparisons between
the OSA patients with and without clinical hypothyroidism.
Male hypothyroid patients were heavier, had a higher
desaturation index, and spent a longer time with an SaO2
< 90% (34.3  38.9 min vs. 13.5  24.4 min, p < 0.05). For
the female OSA patients, there were no differences
between euthyroid and hypothyroid patients.
Table 3 presents a comparison between the men and
women with and without clinical hypothyroidism. Euthyroid
women were older and heavier than euthyroid men, had
a lower minimum SaO2, and spent more time with an SaO2 <
90%. In patients with clinical hypothyroidism, there were no
differences between the genders.
Among the non-OSA patients, a total of 7 of 76 (9.2%)
patients had been previously diagnosed by their treating
physician with clinical hypothyroidism and had started
taking a thyroxine replacement. One (1.4%) patient was
diagnosed with hypothyroidism based on high TSH and low
FT4 levels.
Univariate analysis identified BMI, time SaO2<90 (min),
hypertension, diabetes and female gender as predictors of
clinical hypothyroidism. In the multivariate analysis, only
female gender remained a significant predictor of clinical
hypothyroidism (OR:4.74, p Z 0.006, CI: 1.551e14.490).
Subclinical hypothyroidism
Subclinical hypothyroidism was diagnosed in 27 (11.1%) OSA
patients based on high TSH and normal FT4 levels. None of
these patients had symptoms or signs of hypothyroidism
apart from daytime fatigue and snoring. The prevalence of
subclinical hypothyroidism was 17.3% and 8.0% in female
and male OSA patients, respectively. The demographic and
clinical characteristics of this group revealed 13 males and
14 females, an age range from 18 to 73 years, a BMI range
from 24.3 to 66.3, an AHI range from 12 to 155/h and a TSH
level range from 5.04 to 21.49 mIU/mL.
No differences were found between the euthyroid OSA
patients and the OSA patients with subclinical hypothy-
roidism in either gender. The female OSA patients with
subclinical hypothyroidism had a higher BMI compared to
the male patients (Table 3).
In the non-OSA patients, three females were diagnosed
with subclinical hypothyroidism (4%). The demographic and
clinical characteristics of this group revealed that the ages
ranged from 20 to 47 years, the BMI ranged from 23 to 40.8;
the AHI ranged from 0 to 5/hr and the TSH level ranged
from 5.84 to 9.77 mIU/mL.
Logistic regression analysis demonstrated that none of
the variables studied could predict the presence of
subclinical hypothyroidism.
There were no cases of clinical or subclinical hyperthy-
roidism in the studied group. Three patients in the OSA
group and three patients in the non-OSA group had TSH
levels less than 0.25 mIU/mL. All those with subnormal TSH
levels were on thyroxine replacement (thyroxine
overdosed).Discussion
This study showed a relatively high prevalence of subclin-
ical hypothyroidism among Saudi patients with OSA,
Table 1 Demographics and PSG data of OSA patients with and without clinical hypothyroidism.
Characteristics Clinical Hypothyroidism p-value
Yes (n Z 27) No (n Z 217)
Age 53.3  14.4 47.8  14 0.0567
BMI 43.9  8.6 36.8  9.3 0.0004*
ESS 10.1  7 9.8  6.3 0.8099
Sex (Female) 21 (77.8) 67 (30.9) 0.000*
ESS  10 11 (40.7) 94 (45.2) 0.662
Sleep Efficiency 73.9  21.9 76.7  17.4 0.4460
AHI 63.7  40.1 53.7  36.2 0.1794
Desaturation Index 41.1  28.7 31.5  30.4 0.1203
Time (min) SaO2 < 90 33.7  35 18.8  30 0.0179*
Average O2 90.6  4.4 92.1  6 0.1835
Arousal Index 59.3  38.8 55.8  33.7 0.6249
Smoking history 2 (7.4) 28 (12.9) 0.412
Hypertension 17 (63) 92 (42.4) 0.043*
Ischemic Heart Disease 6 (22.2) 27 (12.4) 0.161
Diabetes Mellitus 15 (55.6) 76 (35) 0.037*
Bronchial Asthma 11 (40.7) 72 (33.2) 0.434
*p < 0.05; BMI: body mass index; ESS: Epworth Sleepiness Scale; AHI: apnea-hypopnea index; CAI: central apnea index.
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our previous report that explored gender differences in
patients with OSA and showed a high prevalence of hypo-
thyroid disease among women. However, that study did not
discriminate between clinical and subclinical hypothy-
roidism.14 The overall prevalence of thyroid disease in
most of the studies conducted in Western societies has
been found to be lower than that reported in this
study.3,8,9,11,12 The prevalence of newly diagnosed clinical
hypothyroidism was not different from previous literature;
however, subclinical hypothyroidism was more prevalent in
this study compared to the majority of published data.
Nevertheless, these results concurred with Resta et al.,
who reported an 11.5% prevalence of subclinical hypothy-
roidism in 78 Italian patients with OSA.9 Possible explana-
tions for the differences in reported prevalence include
the probable effect of race and environmental and socio-
economic factors.17,18,26 Another possible cause for this
disparity in prevalence is a difference in the population
from which referrals came or the referral bias. Some of theTable 2 Within-gender comparison between euthyroid and clin
Characteristics Female
Euthyroidism
(n Z 67)
Clinical hypoth
(n Z 21)
Age (years) 54.7  14.1 54.1  14.4
BMI 43.2  9.7 44.6  7.7
ESS 8.8  5.9 9.5  6.8
Sleep Efficiency 72.5  19 77.8  17.5
AHI 52.2  38.8 59.9  42.6
Desaturation Index 33.4  33.2 36.3  26.2
Time (min) SaO2< 90% 30.8  37.5 33.5  34.8
Minimum O2 73.4  16.6 74.1  12.5
Arousal Index 55  35.9 54.1  39.5
*p < 0.05; BMI: body mass index; ESS: Epworth Sleepiness Scale; AHI:previous studies that explored thyroid disease among OSA
patients measured only the TSH level and considered
patients with a high TSH level as hypothyroid, which did
not provide any differentiation for subclinical hypothy-
roidism.8,12 In this study, we divided patients with high TSH
levels into clinical and subclinical hypothyroidism in a large
group of OSA patients based on the FT4 level. The preva-
lence of newly diagnosed clinical hypothyroidism in this
study is comparable to that found in the majority of
previous studies. However, the prevalence of subclinical
hypothyroidism was relatively high compared to previously
published studies and to the non-OSA patients. In their
series, Kapur et al. reported a prevalence of subclinical
hypothyroidism of 1.4%, which is low compared to our
results. The prevalence of subclinical hypothyroidism has
exhibited racial differences; where the prevalence in
American blacks was one-third that in American whites.23
Furthermore, in this study, a different and more sensitive
assay (ECLIA) was used compared to the radioimmunoassay
used by Kapur et al.ical hypothyroid OSA patients.
Male
yroidism Euthyroidism
(n Z 150)
Clinical hypothyroidism
(n Z 6)
44.7  12.8 50.2  15.6
34.1  7.7* 42  11.5
10.2  6.4 12.2  7.9
78.6  16.4* 60.5  31.2
54.3  35.2 77.3  29
30.7  29.1* 57.8  33.3
13.5  24.4* 34.3  38.9
80.5  12.8* 68.8  20
56.2  32.9 77.3  33.1
apnea-hypopnea index.
Table 3 Gender differences in euthyroid, clinically hypothyroid and subclinically hypothyroid OSA patients.
Characteristics Euthyroid Clinical hypothyroidism Sub Clinical hypothyroidism
Male (n Z 150) Female (n Z 67) Male (n Z 6) Female (n Z 21) Male (n Z 13) Female (n Z 14)
Age (years) 44.7  12.8* 54.7  14.1 50.2  15.6 54.1  14.4 52.8  14.1 51  13.9
BMI 34.1  7.7* 43.2  9.7 42.0  11.5 44.6  7.7 32.8  6.3* 45.1  11.6
ESS 10.2  6.4 8.8  5.9 12.2  7.9 9.5  6.8 8.5  5.9 7.6  5.3
Sleep Efficiency 78.6  16.4* 72.5  19 60.5  31.2 77.8  17.5 73.7  21.5 66.7  18.6
AHI 54.3  35.2 52.2  38.8 77.3  29 59.9  42.6 60  33.1 57.6  46.3
Desaturation Index 30.7  29.1 33.4  33.2 57.8  33.3 36.3  26.2 29.5  22.9 38.7  41.6
Time (min) SaO2<90 13.5  24.4* 30.8  37.5 34.3  38.9 33.5  34.8 17.3  29.4 27.9  38.8
Minimum O2 80.5  12.8* 73.4  16.6 68.8  20.0 74.1  12.5 82.1  8.5 79.5  13
*p < 0.05; BMI: body mass index; ESS: Epworth Sleepiness Scale; AHI: apnea-hypopnea index.
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women with hypothyroidism. While age, BMI, respiratory
parameters, the arousal index and comorbid conditions did
not differ between the euthyroid and hypothyroid female
OSA patients, the AHI, the desaturation index, and the time
spent with an SaO2<90% were significantly greater in the
male hypothyroid OSA patients compared to the euthyroid
OSA patients. Gender differences were apparent between
the euthyroid men and women. Euthyroid females with OSA
were older, heavier, and spent more time with an SaO2<90%
compared to the males with OSA. However, the differences
were less apparent in the clinically hypothyroid group with
OSA (Table 3). This suggests that women with clinical
hypothyroidism may not necessarily have more severe OSA
than euthyroid women. These findings concur with those of
Miller et al., who reported no difference in age, BMI, the
respiratory disturbance index or the arousal index between
euthyroid and hypothyroid women for a group of 118
women with OSA.12
Currently, no evidence exists of any long-term benefit
for replacement therapy in patients with subclinical hypo-
thyroidism with regard to survival or cardiovascular
morbidity.15,23,27 Nevertheless, available data indicate that
thyroxine replacement may be beneficial in certain condi-
tions, such as resulting in the improvement of some
parameters of lipid profiles and left ventricular function.27
Studies that assessed the effects of replacement therapy in
OSA patients with clinical hypothyroidism demonstrated
clear benefits in nonobese patients.1 In contrast, the
improvement was less impressive in obese patients.1
However, the effect of treating subclinical hypothyroidism
in OSA patients has not yet been thoroughly assessed. A
small study that examined the effects of treating subclin-
ical hypothyroidism in patients with OSA reported no
changes in the PSG parameters.28
Bronchial asthma prevalence among OSA patients in this
study was relatively high. Nevertheless, asthma is common
among Saudis and a previous study estimated the preva-
lence of asthma among Saudi OSA patients as 35.1%.29,30
Another interesting finding of this study is the high diag-
nostic yield of PSG in patients with clinical suspicion of OSA.
Around 78% of the patients suspected clinically to have OSA
were confirmed to have OSA using PSG. This finding concurs
with previous studies; however, it has not been stressed or
discussed previously.One limitation of the studies that assessed the preva-
lence of subclinical hypothyroidism in OSA patients is that
they did not account for the possibility of transient
subclinical hypothyroidism. Repeating the TSH and FT4
measurements after 2e12 weeks may exclude some
patients with transient hypothyroidism and result in a lower
number of patients initially considered to have subclinical
hypothyroidism. We have repeated the thyroid function
measurements for most (20 patients) but not all patients.31
In summary, our results suggest that the prevalence of
newly diagnosed cases of clinical hypothyroidism is too low
in OSA patients to warrant routine testing for thyroid
function. In contrast, subclinical hypothyroidism was
common among patients with OSA; however, the benefit of
treating this condition is uncertain. Therefore, we do not
recommend routine thyroid function testing in OSA patients
unless hypothyroidism is suspected on the basis of symp-
toms and physical signs.
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